CYRX arrives at Thursday's Q1 earnings call with short sellers decisively pulling back, analysts raising targets, and the stock up 52% over the past month — making this week's print the first genuine test of whether the rally has fundamental legs.
Shorts have quietly capitulated over the past six weeks. SI as a percentage of the free float has fallen from above 5.2% in late April to 3.96% now — a drop of roughly a quarter-point in a single week. The lending market is extraordinarily loose for a stock that has moved this aggressively: availability of shares to borrow has exploded to over 5,000% of short interest, meaning there are far more shares available in the borrow pool than there are shorts actually in the market. Cost to borrow has drifted to just 0.44% annualised, down 20% on the week and among the cheapest in the sector. The ORTEX short score has also fallen from 43 on May 20 to 35 now — a meaningful easing of short-side conviction. None of this looks like a market pricing in further downside.
Options tell a similar story of benign positioning. The put/call ratio is running at 0.22, essentially in line with its 20-day average of 0.22 and well below the 52-week high of 0.49. There is no defensive hedging building ahead of Thursday's report. Options traders appear comfortable with the current setup, not scrambling for downside protection.
The Street has been busy lifting its pencil. Craig-Hallum raised its target from $15 to $20 today while maintaining its Buy — the freshest and most aggressive move in the sequence. Keybanc lifted its Overweight target to $17 from $15 in late May. That follows a cluster of upgrades from Needham, BTIG, and Guggenheim in early May, all of which maintained Buy ratings and nudged targets into the $12–$17 range after what appears to have been a strong prior print. With the stock at $15.74, the mean analyst target of $15.33 has been effectively caught — Craig-Hallum's new $20 target is the clearest signal that at least one firm thinks the stock still has room. The bull case centres on Cryoport's positioning as the infrastructure layer for cell and gene therapy logistics: sticky revenue, a growing approved-therapy base, and meaningful operating leverage potential. Bears point to the finite universe of currently approved therapies, competition in cold-chain logistics, and macro pressure on the industrial MVE business.
Valuation has re-rated sharply alongside the price. The EV/EBITDA multiple has compressed by roughly 33% over the past 30 days — not because earnings surged, but because the market is repricing the story. The price-to-book ratio has moved from roughly 1.09 to 1.68 over the same window. At a negative trailing P/E the stock is priced on future optionality rather than current earnings, which makes the forward guidance on Thursday disproportionately important.
A note on the institutional register: Vanguard Capital Management added the entirety of its 2.1m-share position in Q1, while MAK Capital added 224,000 shares. The largest holder, Cadian Capital, trimmed marginally. Insider activity is dated — the most recent trades on record are small routine sells from March at around $8, well below today's price; they carry limited read-through at current levels.
The last two earnings prints sent the stock sharply higher — the May 2026 report produced a 17.8% single-day gain and a 27% five-day move, while a separate May event logged a more modest 4.7% one-day move. That pattern gives options traders a historical basis for not hedging aggressively, and it also raises the bar: a repeat of recent beats is probably priced in. What to watch on Thursday is management's revenue guidance for the second half, specifically whether commercial therapy volumes are tracking above the currently-approved baseline — because that is the single variable the bear case says the market is overestimating.
See the live data behind this article on ORTEX.
Open CYRX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
